Eupraxia Pharmaceuticals (EPRX) Retained Earnings (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Retained Earnings data on file, last reported at -$182.2 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 4320.58% year-over-year to -$182.2 million in Q1 2026; TTM through Mar 2026 was -$182.2 million, a 4320.58% decrease from a year earlier, with the FY2025 full-year figure at -$169.6 million, down 3975.9% from the prior year.
• Retained Earnings for Q1 2026 stood at -$182.2 million, down from -$169.6 million in the prior quarter.
• Over the last five years, Retained Earnings for EPRX reached as high as -$2.7 million in Q4 2023 and fell as low as -$182.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$99.3 million across 5 years, with a median of -$117.6 million in 2024.
• Across the five-year window, Retained Earnings jumped 96.5% in 2023 and tumbled 4320.58% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$77.3 million in 2022, then surged by 96.5% to -$2.7 million in 2023, then tumbled by 53.72% to -$4.2 million in 2024, then tumbled by 3975.9% to -$169.6 million in 2025, then slipped by 7.46% to -$182.2 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$182.2 million in Q1 2026, -$169.6 million in Q4 2025, and -$152.9 million in Q3 2025.